|Home | About | Journals | Submit | Contact Us | Français|
Expression of non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) inhibits gastrointestinal tumorigenesis in NAG-1 transgenic mice (C57/BL6 background). In the present study, we investigated whether NAG-1 protein would alter urethane-induced pulmonary lesions in NAG-1 transgenic mice on an FVB background (NAG-1Tg+/FVB). NAG-1Tg+/FVB mice had both decreased number and size of urethane-induced tumors, compared to control littermates (NAG-1Tg+/FVB = 16 ± 4 per mouse versus control = 20 ± 7 per mouse, p<0.05). Urethane-induced pulmonary adenomas (PAs) and adenocarcinomas (PACs) were observed in control mice, but only PAs were observed in NAG-1Tg+/FVB mice. Urethane-induced tumors from control littermates and NAG-1Tg+/FVB mice highly expressed proteins in the arachidonic acid pathway (cyclooxygenases 1/2, prostaglandin E synthase, and prostaglandin E2 receptor) and highly activated several kinases (phospho-Raf-1 and phospho-ERK1/2). However, only urethane-induced p38 MAPK phosphorylation was decreased in NAG-1Tg+/FVB mice. Furthermore, significantly increased apoptosis in tumors of NAG-1Tg+/FVB mice compared to control mice was observed as assessed by caspase 3/7 activity. In addition, fewer inflammatory cells were observed in the lung tissue isolated from urethane-treated NAG-1Tg+/FVB mice compared to control mice. These results paralleled in vitro assays using human A549 pulmonary carcinoma cells. Less phosphorylated p38 MAPK was observed in cells over-expressing NAG-1, compared to control cells. Overall, our study revealed for the first time that NAG-1 protein inhibits urethane-induced tumor formation, probably mediated by the p38 MAPK pathway, and is a possible new target for lung cancer chemoprevention.
Lung cancer is the leading cause of cancer-related death in men and women in the United States, and pulmonary adenocarcinoma (PAC) is the most common type of lung cancer, according to the American Cancer Society. Rodents develop chemically-induced lung tumors with molecular and histological features similar to PAC in humans (1–4). In animal models of lung adenocarcinoma including rodents, urethane has been used as a carcinogen that specifically induces the development of lung tumors from alveolar type II pneumocytes and Clara cells (2, 4–6).
Nonsteroidal anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1) is highly induced by many drugs and chemicals that influence development of tumorigenesis. Also known as a macrophage inhibitory cytokine-1, growth and differentiation factor-15, placental transforming growth factor β, prostate-derived factor, and placental bone morphogenetic protein (7), the NAG-1 protein shows broad activities in various tissues. However, its molecular mechanisms, the receptor or molecules interacting with NAG-1 are incompletely characterized. As previously published by our group and others, NAG-1 has anti-inflammatory, anti-proliferative, and pro-apoptotic effects in several types of cancer in vitro (8–10) and is induced by certain drugs and chemicals. These include NSAIDs (8), chemopreventive dietary compounds (11–14), and PPARγ ligands (15–17). Furthermore, NAG-1 is an important downstream target of the tumor suppressor gene p53 (11), EGR-1 (18), and the PI3K/AKT/GSK-3β pathways (19). Thus, NAG-1 plays a pivotal role in anti-tumorigenesis induced by chemopreventive compounds.
Transgenic mice (NAG-1Tg+/BL6) expressing human NAG-1 have been developed by our group (9), and we have found that NAG-1Tg+/BL6 mice are resistant to chemically-and genetically-induced intestinal polyp formation. An approximate 50% reduction in polyps was observed after azoxymethane treatment of NAG-1Tg+/BL6 and 40% inhibition of polyp formation in the intestine by crossing NAG-1Tg+/BL6 mice with ApcMin+ mice, as compared to control littermates. These results indicate that NAG-1 is a potential tumor suppressor gene in colorectal cancers (9). Since a BL6 background model is not susceptible to chemically-induced lung cancer, we have back-crossed NAG-1Tg+/BL6 mice with the FVB background to generate the NAG-1 transgenic mice with the FVB background (NAG-1Tg+/FVB) and investigated whether the expression of human NAG-1 would suppress urethane-induced PAC formation in a mice model. There are a few studies examining a potential role of NAG-1 in lung tumorigenesis (20, 21), based on data showing the downregulation of NAG-1 expression in lung tumors compared to normal tissue.
In this report, we describe the role of NAG-1 as an anti-tumorigenic protein in tumors in a urethane-induced mice model. The over-expressed human NAG-1 protein in NAG-1Tg+/FVB mice inhibited the formation of lung tumors through down-regulation of the p38 MAPK signaling pathway and induced apoptosis through the activation of caspase 3/7. In addition, we have confirmed our findings in vitro using human A549 pulmonary carcinoma cells. A decreased phosphorylation of p38 MAPK was observed in cells over-expressing NAG-1 compared to the control cells after various treatments. Data from this study strongly suggest that NAG-1 protein and its signaling pathway could be potential new targets for prevention and/or treatment of lung cancer.
Urethane was purchased from Sigma (Sigma-Aldrich, St. Louis, MO), cigarette smoke condensate (CSC) was obtained from Murty Pharmaceuticals Inc. (Lexington, KY), epidermal growth factor (EGF) and insulin-like growth factor-1 (IGF-1) were purchased from BD Biosciences (Bedford, MA), and prostaglandin E2 (PGE2) was purchased from Cayman Chemical Co. (Ann Arbor, MI). NAG-1 antibody was previously described (8). Microsomal PGES (mPGES) antibody was purchased from Oxford Biomedical Research (Oxford, MI), and lysozyme antibody was purchased from Dako North America Inc. (Carpinteria, CA). Antibodies for COX-2, cyclin D1, p27, p53 and actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). COX-1 and EP2 antibodies were obtained from Cayman Chemical Co. Phospho-Raf-1 (Ser259), phospho-p38 MAP kinase (Thr180/Tyr182), p21, and cleaved caspase-3 (Asp175) antibodies were purchased from Cell Signaling Technology (Beverly, MA). Human A549 lung carcinoma cell line was obtained from American Type Culture Collection (ATCC, Manassas, VA). The cells were maintained in Ham’s F12K medium supplemented with 10% fetal bovine serum and antibiotics (100 I.U. penicillin and 100 µg/ml streptomycin), and grown in an atmosphere of 5% CO2 at 37°C.
All animal research procedures were approved by the University of Tennessee Institutional Animal Care and Use Committee and were in accordance with NIH guidelines. NAG-1 transgenic mice were originally developed on a C57BL/6 genetic background (9). NAG-1Tg+/BL6 mice were backcrossed to FVB strain mice for 8 generations. Mice were maintained at 22 ± 2°C on a 12 h light/dark cycle with free access to standard rodent chow and tap water. Eleven-week-old control littermates (NAG-1Tg-/FVB, n=11) and NAG-1 transgenic mice (NAG-1Tg+/FVB, n=10) received i.p. injections of urethane (1 mg of urethane dissolved in 0.9% NaCl/g body weight) or 0.9% NaCl alone once per week for 6 weeks (Fig. 1A). At age 30 weeks mice were sacrificed, and lung tissues were collected and kept in RNAase later solution for protein and RNA analysis, and in 10% neutral-buffered formalin for paraffin embedding.
Surface (gross) lung lesions were counted by three blinded readers after removing the lung from sacrificed mice. The microscopic evaluation of lung lesions was done using H&E-stained lung tissue slides.
Lung tissues were formalin-fixed, embedded in paraffin, and sectioned at 5 µm. Immunohistochemical staining was performed as described previously (3). The images were captured by an Olympus DP70 camera (Olympus Optical Col, Japan) attached to an Olympus microscope. For scoring of lysozyme staining in inflammatory cells (22), slides were reviewed by three blinded readers. For each lung specimen (n=3 per treatment group), six normal cross sectional lung areas, four edge areas of neoplasia and one central area of neoplasia were evaluated and scored for intensity (1=weak, 2=moderate, 3=intense staining). Scores for number and intensity of staining of inflammatory cells were then multiplied and normalized to the control group.
To measure the diameter of neoplasia, photographic images (magnification 2×) of the lung lobes were taken. The diameters of the neoplasia were measured by the Olympus software package. For each treatment group, approximately 30 neoplastic foci were measured and divided into four groups according to size. For evaluation of percentage of cross sectional area occupied by neoplasia, H&E lung images of each mouse were taken at magnification 2× and measured using Scion Image software to compare the area of normal and neoplastic pulmonary tissue. Measured areas of all neoplasia from the same lung were combined, divided by the area of the whole lung and multiplied by 100 to get a result as a percentage. The results were presented as a mean ± S.D. for each treatment group, and statistical analyses were performed.
Total RNA was isolated from mice lung tissue using an RNeasy mini kit (Qiagen), and then cDNA was synthesized from 1 µg of total RNA using an iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA) according to the manufacturer’s protocols as described previously (23). The primer sequences used in our study were h-NAG-1 (F: 5’-cggaacgagggcaacctgcacagcc-3’, R: 5’-tatgcagtggcagtctttg-3’) and m-Gapdh (F: 5’-caggagcgagaccccactaacat-3’, R: 5’-gtcagatccacgacggacacatt-3’).
Lung tissues were homogenized and then sonicated in ice-cold RIPA buffer (1XPBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease and phosphatase inhibitors (1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 mM PMSF, 1 mM Na3VO4, and 25 mM NaF). Proteins from A549 cells were used for immunoblotting as described previously (24).
The Caspase-Glo 3/7 Assay kit (Promega, WI) was used to measure apoptosis in mouse lung tissue following the manufacturer’s protocol. Briefly, the tissue lysates were prepared using RIPA buffer, and a total of 30 µg of proteins were added into 96-well tissue culture plates with white walls and a clear bottom, and an equal amount of luminescence substrate for caspase 3/7 was added to each sample. After 1 h incubation in the dark at room temperature, the luminescence was measured in a plate-reading luminometer (FL×800) as directed by the manufacturer (BioTek Instruments, Winooski, VT).
TACS2 TdT-DAB In Situ Apoptosis detection kit was purchased from Trevigen (Gaithersburg, MD) and used to detect apoptotic cells. Briefly, the lung sections were deparaffinized, rehydrated, and washed in 1× PBS. Samples were incubated in cytonin solution for 30 min at room temperature, washed in 1× PBS, immersed in quenching solution for 5 min, and then washed in 1× PBS. After washing, the slides were immersed in 1× TdT labeling solution for 5 min followed by incubation in labeling reaction mix for 1 h. Then the samples were washed with stop buffer and incubated with strep-HRP solution, and bound conjugate was visualized by DAB staining. The samples were counterstained by Methyl Green staining. As a positive control, we used a lung tissue pretreated with TACS-Nuclease to generate DNA breaks in cells. The results were analyzed under a microscope.
All transfection experiments were performed using Lipofectamine2000 reagent (Invitrogen Corporation, Carlsbad, CA) according to the manufacturer’s instructions, as described previously (8) After transfection and serum starvation, the cells were treated with indicated compounds for 0.5 and 2 h.
We used the Student t test and ANOVA test to analyze the data. Results were considered statistically significant at p<0.05*, p<0.01**, and p<0.001***.
To explore NAG-1’s role in lung tumorigenesis, NAG-1Tg+/BL6 mice were bred with wild FVB strain mice to generate NAG-1Tg+/FVB mice, which are a more susceptible model for lung carcinogenesis (22). To evaluate the effects of NAG-1 on lung tumorigenesis, urethane was used to induce pulmonary adenomas (PAs) and adenocarcinomas (PACs) in mice (6). Eleven-week-old NAG-1Tg+/FVB (n=10) and control littermate mice (n=11) received i.p. injections of urethane or 0.9% NaCl alone once per week for 6 weeks. Fourteen weeks after the last urethane treatment, mice were sacrificed and lung tissues were examined and collected for further analysis (Fig. 1A).
NAG-1Tg+/BL6 have been reported viable and fertile with no distinguishable behavioral, clinical or histopathological phenotype except that the mice had reduced body weight compared to the control littermates (9). A similar decrease in body weight was observed in the NAG-1Tg+/FVB compared to control mice (Fig. 1B; NAG-1Tg+/FVB = 24.8 ± 1.1 g per mouse vs. control = 32.3 ± 5.2 g per mouse at 30 weeks, p<0.001). However, the weight of dissected lungs from NAG-1Tg+/FVB mice was not significantly reduced compared to lungs from control mice (NAG-1Tg+/FVB = 0.219 ± 0.03 g per mouse vs. control = 0.245 ± 0.01 g per mouse, p=0.14).
NAG-1 expression in lungs of NAG-1Tg+/FVB mice was confirmed by RT-PCR and Western blotting (WB) analysis (Fig. 1C). RNA transcripts of the human NAG-1 gene were amplified from lung samples of NAG-1Tg+/FVB mice, whereas no amplified products were detectable in control mice (Fig. 1C, top). Cell lysates from urethane-treated lung tissue were subjected to WB analysis, and NAG-1 protein was detected only in tissue obtained from the NAG-1Tg+/FVB mice (Fig. 1C, bottom). NAG-1 expression in NAG-1Tg+/FVB mice was also seen in other tissues, including skin, colon, brain, and kidney (data not shown).
To characterize the urethane induced-lesions, lungs were dissected from mice and evaluated by gross examination and light microscopy. There was a 100% incidence of lung lesions in both the control and NAG-1Tg+/FVB mice treated with urethane; however, no lung lesions were observed in saline-treated groups (data not shown). To determine whether NAG-1 expression alters urethane-induced lung tumorigenesis, surface lung tumors were counted (Fig. 2A). The NAG-1Tg+/FVB mice had a modest, but significantly lower number of urethane-induced pulmonary tumors, compared to the control littermates (NAG-1Tg+/FVB = 16 ± 4 per mouse vs. control = 20 ± 7 per mouse, p<0.05). The light microscopic examination of multiple lung sections H&E stained with roughly equivalent cross-sectional areas revealed the location of most neoplasia at the periphery of the lungs (Fig. 2B). Lungs from urethane-treated control mice had significantly more lesions compared to urethane-treated NAG-1Tg+/FVB mice (NAG-1Tg+/FVB = 7.4 ± 2.4 per lung vs. control = 10.7 ± 3.8 per lung, p<0.05). No significant pulmonary pathology was observed in the lungs from the saline-treated control mice (data not shown). In the lung sections from the urethane-treated control (n=11) and NAG-1Tg+/FVB mice (n=9), foci of hyperplasia (Fig. 2C), atypical adenomatous hyperplasia (Fig. 2C) and multiple pulmonary epithelial neoplasia were present. The majority of the neoplastic foci were considered adenomas (Fig. 2C), characterized by being well-differentiated, compressing the surrounding tissues (Fig. 2C), with no to minimal mitotic activities, and solid to mixed (solid and papillary) architectural pattern. Approximately 20% of the neoplasias in the urethane-induced control mice were considered adenocarcinomas (Fig. 2C) with localized fingering invasion into surrounding parenchyma or airways, and with an average mitotic index of 3.2 mitotic figures per 40× objective field; however, no metastasis was observed. Interestingly, no adenocarcinomas were identified in lung sections from the urethane-treated NAG-1Tg+/FVB mice (n=10). The results are based on analysis of the sections from lung lobes of each mouse, so obtained data are from only a limited area of the lung. Approximately the same areas were analyzed from the each treatment group. The diameters of tumors from the NAG-1Tg+/FVB mice (n=29) were compared to the diameters of neoplasia from the control littermates (n=33). Most of the tumors of the control mice were more than 0.5 mm in size, whereas 58% of NAG-1Tg+/FVB mice had lung tumors with diameters more than 0.5 mm in size (Fig. 2D). In general, the tumors in the NAG-1Tg+/FVB mice were smaller than the tumors in the control mice. Overall, NAG-1Tg+/FVB mice had reduced tumor amount and size, with no adenocarcinomas compared to control littermates, indicating the possible role of NAG-1 in inhibition of lung tumor progression.
To further characterize the effects of NAG-1 protein on lung tumorigenesis and to identify possible mechanisms involved in pulmonary tumor growth and progression, we examined protein expression in lung tissue from urethane-treated NAG-1Tg+/FVB and control mice. Proteins of the arachidonic acid pathway play important roles in lung tumorigenesis 25), and several proteins involved in this pathway were examined. Expression of COX-2, COX-1, and prostaglandin E2 synthase (PGES) was up-regulated in lung tumor tissue from both treated control and NAG-1Tg+/FVB mice (Fig. 3A). The expression of EP2 and EP4, two members of the prostaglandin E receptor family, were also examined; however, we were not able to detect EP4 receptor expression in mice lung tissue (data not shown). In contrast, the EP2 receptor was highly expressed in lung tumor tissues from both NAG-1Tg+/FVB and control mice. Expression of several other signaling proteins involved in lung tumorigenesis was examined. The active Raf-1 and ERK1/2 play an important role in lung tumorigenesis (24, 26, 27), and an increased activation of Raf-1 and ERK1/2 was observed in tumor tissue from both NAG-1Tg+/FVB and control mice (Fig. 3B). We also examined cell cycle-related proteins, including cyclin D1, p53, p27, and p21. However, as shown in Fig. 3C, the expression of these proteins was not affected by NAG-1 over-expression.
Urethane-induced phosphorylation of p38 MAPK at Thr180/Tyr182 was increased in tumor tissue compared to normal tissue from control mice. In contrast, the phosphorylation of p38 MAPK was significantly lower in tumor and normal tissue isolated from NAG-1Tg+/FVB mice, suggesting that the expression of NAG-1 inhibits phosphorylation of p38 MAPK (Fig. 3B). There were no significant differences in NAG-1Tg+/FVB and control mice in the expression of either phospho-AKT or phospho-SAPK/JNK (data not shown). Our data suggest that NAG-1 expression may cause alteration of p38 MAPK in urethane-induced lung tumorigenesis.
Immunohistochemical analysis was also performed to confirm and localize protein expression in the pulmonary tissues. Using an antibody specific for the phosphorylated form of p38 MAPK at Thr180/Tyr182, there was a substantial decrease in staining intensity for the active p38 MAP kinase in nuclei and cytoplasm in the lung tumors of NAG-1Tg+/FVB mice (data not shown).
It has been reported that NAG-1 induces caspase activity (28). To evaluate the possible involvement of NAG-1 in regulating lung tumorigenesis through apoptosis, caspase-3/7 activities in normal and tumor tissues of the lungs were measured. The caspase-3/7 activities in lung tumors were highly significantly increased in NAG-1Tg+/FVB mice, compared to control mice and compared to the normal lung of NAG-1Tg+/FVB mice (Fig. 4A). There was no significant difference in caspase-3/7 activities between the normal lungs from control and NAG-1Tg+/FVB mice.
To further demonstrate that NAG-1 protein modulates apoptotic pathways in lung tumorigenesis, the lung tissues were treated with an antibody specifically recognizing only the cleaved form of caspase 3. Immunohistochemical staining was positive for active caspase 3, localized to the cytoplasm in the tumors of NAG-1Tg+/FVB mice, but not in the tumors of control mice (data not shown). The appearance of apoptosis was confirmed by TUNEL assay as shown in Fig. 4B.
In addition to NAG-1’s role in anti-tumorigenesis, it has been shown that NAG-1 affects anti-inflammatory activity by reducing tumor necrosis factor-α (TNF-α) secretion in macrophages (29). Urethane- or cigarette smoke-induced lung tumor formation may be potentiated by inflammation (22, 30). To check the role of NAG-1 in inflammation, we performed immunohistochemical staining of lysozyme to detect the presence of inflammatory cells in lung tissue. Lysozyme is an enzyme highly expressed in cytoplasmic granules of the granulocytic series of inflammatory cells, such as macrophages and polymorphonuclear neutrophils (Fig. 5A). As shown in Fig. 5B, NAG-1Tg+/FVB mice had a significant 50% reduced number of lysozyme positive cells in the lung over control mice (*p<0.05). Thus, this suggests that NAG-1 suppresses urethane-induced inflammation in lung tissue.
To verify the role of NAG-1 protein in inhibition of lung tumors in NAG-1Tg+/FVB mice through the p38 MAPK, human A549 lung carcinoma cells were transiently transfected with a plasmid construct containing the human NAG-1 gene. After transfection, A549 cells were treated with TPA (20 nM), cigarette smoke condensate (CSC, 40 µg/ml), EGF (100 nM), IGF-1 (100 nM), and PGE2 (50 nM) for 0.5 and 2 h. As shown in Fig. 6A, treatment with CSC had the ability to induce phosphorylation of p38 MAPK at 2 h, and its expression was diminished in the presence of NAG-1 protein. Similar results were observed when A549 cells were treated with both growth factors EGF and IGF-1, as well with inflammatory cytokine PGE2 (Fig. 6B and 6C). Interestingly, NAG-1 protein had no effect on the phosphorylation of p38 MAPK after treatment with TPA (Fig. 6A). In addition, NAG-1 protein had no effect on the phosphorylation of p42/p44 MAP kinases after activation by all tested agents in transiently transfected A549 cells (data not shown).
NAG-1 has anti-proliferative and pro-apoptotic effects in several types of cancer in vitro and is highly induced by many chemopreventive compounds (7). NAG-1 is highly expressed in normal tissue of the small intestine, and it is significantly reduced in human colorectal carcinomas and neoplastic intestinal polyps of ApcMin+ mice (31). In the human lung, NAG-1 was reported to be highly expressed in normal tracheobronchial epithelium, but absent in several tumor tissues from adenoma, small cell, large cell and squamous cell carcinomas (20). Those findings are in agreement with observations in this study, in which the expression of human NAG-1 protein plays an important role in lung tumorigenesis.
NAG-1 transgenic mice on a C57BL/6J background were generated using the Cre/LoxP system (9). NAG-1Tg+/BL6 mice were viable and fertile with no apparent phenotype other than a reduction in body weight compared to non-transgenic littermate controls. In this study, we generated NAG-1Tg+/FVB mice, because the FVB strain is a more susceptible model for urethane-induced lung tumorigenesis. With more than 8 generations of backcross with wild type mice with FVB background, we found that body weight was still less in NAG-1Tg+/FVB mice compared to the control mice (Fig. 1B), indicating that NAG-1-induced body weight reduction is seen not only in C57BL/6J mice, but also in other strains of mice.
It has been known that urethane-induced lung tumors in rodents provide an excellent model to determine the efficacy of tumor suppressor genes as a preventative method, as well to evaluate mechanisms responsible for anti-tumorigenesis. This experimental system can be vigorously examined throughout lung carcinogenesis, from the appearance of early pre-neoplastic proliferative lesions and small adenomas to malignancy. Urethane-induced pulmonary adenomas predominantly occur in the periphery of the lung (2, 4, 6). Primary mouse lung tumors share morphological, histological and molecular characteristics with human lung tumors. Our data suggest that NAG-1Tg+/FVB mice had a significantly lower incidence of urethane-induced pulmonary lesions compared to the control littermates, with the localization of most neoplasia at the periphery of the lungs. Histology of the lung sections from urethane-treated control and NAG-1Tg+/FVB mice revealed the formation of hyperplasia and pulmonary epithelial neoplasia (Fig. 2C). Nearly all neoplasia were considered adenomas, but only in the control mice, urethane also induced adenocarcinomas with typical invasion into surrounding tissue. However, no adenocarcinomas were observed in the lung tissue sections from NAG-1Tg+/FVB mice. Based on these data, NAG-1 may play a role in inhibition of malignancy in lung tumorigenesis. Similarly, another study suggests that NAG-1 expression induces the differentiation of normal tracheobronchial epithelium (20), although the defined biological role of NAG-1 protein in the epithelium is not yet fully understood.
Chronic inflammation is linked to carcinogenesis in several organ systems including the colon and lung, and inflammatory cells increase expression of factors that may support the growth, angiogenesis and metastasis of cancer cells. The p38 MAPK activation is well associated with extracellular matrix remodeling, inflammation, and contractile dysfunction of the heart (32). However, the role of p38 MAPK in tumorigenesis depends on cell type and stimuli (33). In contrast to a number of publications discussing the role of the p38 MAPK pathway as an anti-tumorigenic, many publications have provided evidence for its role in the progression of tumorigenesis via increasing production of pro-inflammatory cytokines. For example, recently published results by Stathopoulos et al. (22) showed that urethane-induced lung tumor formation is initiated by inflammation through the activation of NF-kB. Another study shows that mice, after exposure to cigarette smoke, show increased lung inflammatory cell influx, activation of NF-κB and p38 MAPK, and increased levels of MMP-9 and proinflammatory cytokines, such as TNF-α and IL-6 (30). Since NAG-1 appears to have anti-inflammatory activity by reducing TNF-α secretion in macrophages (29) and p38 MAPK was inactivated in the NAG-1Tg+/FVB mice after urethane exposure, our data indicated that p38 MAPK could be a novel downstream target of NAG-1’s signaling pathway, resulting in the reduction of inflammatory cells (Fig. 5) and potentially leading to inhibition of the lung tumorigenesis. The importance of NAG-1 in lung tumorigenesis was confirmed by in vitro experiments. Our data revealed that CSC-, IGF-1-, EGF-, or PGE2 -induced phosphorylation of p38 MAPK was down-regulated in the presence of over-expressed NAG-1 in human A549 lung carcinoma cells (Fig. 6A, 6B, and 6C).
Western blot for NAG-1 in A549 cells (Fig. 6) and in mice lung tissue (Fig. 1C) revealed two bands that migrate as a doublet (35 kDa) on SDS-PAGE gels. This phenomenon was observed in other cell lines, such as human LNCaP prostate carcinoma cells (34). We speculated that NAG-1 gene has two translational initiation codons, which produce two different peptides with 13 amino acid differences. Given that both bands are induced by several anti-cancer compounds including vitamin D (35), and Western blot with NAG-1 peptide showed disappearance of both bands, we strongly believe that these are from different usage of the translation initiation start site. However, the biological function of the short form is still unknown and needs to be addressed in future studies.
Prevention by eliminating tumor promoters, early diagnosis and new target treatment are keys to reduce the numbers of deaths caused by lung cancer. In the present study, we propose anti-tumorigenic activities of NAG-1 in lung cancer. Over-expressed human NAG-1 reduced tumor number and size and protected the progression of urethane-induced pulmonary neoplasia in mouse models. The newly identified NAG-1 downstream molecular target was p38 MAPK. NAG-1 had pro-apoptotic activity by increasing caspase 3/7 activities. To our knowledge, we have shown for the first time that NAG-1 has anti-inflammatory activity in lungs through the inhibition of inflammatory cells. Our in vivo data were also confirmed by in vitro data using human A549 lung carcinoma cells over-expressing human NAG-1. We conclude that NAG-1 plays a role as a tumor suppressor gene in lung tumorigenesis, and the elucidation of NAG-1 downstream signaling can help us to better understand the regulation of lung cancer prevention (Fig. 6D).
We thank Ms. Misty R. Bailey (University of Tennessee) for her critical reading of the manuscript, Dr. Michael F. McEntee for valuable suggestions, and Dr. Heon-Suk Lee and Ms. Xiuoon Li for their technical assistance.
Financial Support: This work was supported by grants from the American Cancer Society (CNE-111611), National Institutes of Health (RO1CA108975), The University of Tennessee Center of Excellence in Livestock Diseases and Human Health to SJB, and in part by NIEHS/NIH intramural research program to TEE.
Conflict of interest statement: The authors declare no conflict of interest.